Abstract
Background: Cigarette smoking has been associated with increased plasma homocysteine levels. Although hyperhomocysteinemia may mediate some of the adverse cardiovascular consequences of smoking cigarettes, the effects of smoking cessation and smoking reduction on homocysteine levels have not been evaluated previously.
Hypothesis: The purpose of this study was to determine the effects of smoking cessation and smoking reduction on plasma homocysteine levels.
Methods: Fifty‐one healthy subjects who smoked 35.9 ± 6.4 cigarettes daily were randomized to continue smoking, reduce smoking to 4‐8 cigarettes daily, or to stop smoking. A nicotine inhaler and individualized counseling were provided as aids to smoking cessation.
Results: In subjects who quit smoking, homocysteine levels decreased by 11.6%, from 8.58 ± 2.31 to 7.53 ± 2.26 μmol/l (p = 0.013). Significant changes in homocysteine levels were not observed in subjects who reduced smoking or continued to smoke.
Conclusion: A “harm reduction” strategy of reducing cigarette use may not be sufficient for reducing the vascular risk associated with smoking cigarettes.
Keywords: homocysteine, tobacco, atherosclerosis
Full Text
The Full Text of this article is available as a PDF (29.7 KB).
References
- 1. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland M, Kvale G: Total plasma homocysteine and cardiovascular risk profile: The Hordaland Homocysteine Study. J Am Med Assoc 1995; 274:1526–1533 [DOI] [PubMed] [Google Scholar]
- 2. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LD, Ueland PM, Palma‐Reis RJ, Boers GHJ, Sheahan RJ, Israelsson BO, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales L, Armando C, Parrot‐Rouland FM, Tan KS, Higgins I, Garcon D, Medrano MJ, Candito M, Evans AE, Andria G: European Concerted Action Project. Plasma homocysteine as a risk factor for vascular disease. J Am Med Assoc 1997; 277:1775–1781 [DOI] [PubMed] [Google Scholar]
- 3. Glueck CJ, Shaw PS, Lang JE, Tracy T, Sieve‐Smith L, Wang Y: Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol 1995; 75:132–136 [DOI] [PubMed] [Google Scholar]
- 4. Bergmark C, Mansoor MA, Swedenborg J, de Faire U, Svardal AM, Ueland PM: Hyperhomocysteinemia in patients operated for lower extremity ischaemia below the age of 50: Effect of smoking and extent of disease. Eur J Vasc Surg 1993; 7:391–396 [DOI] [PubMed] [Google Scholar]
- 5. Williams RR, Malinow MR, Hunt SC, Upson B, Wu LL, Hopkins PN, Stults BN, Kuida H: Hyperhomocyst(e)inemia in Utah siblings with early coronary disease. Coron Art Dis 1990; 1:681–685 [Google Scholar]
- 6. Malinow MR, Bostom AG, Krause RM: Homocystein(e), diet, and cardiovascular diseases: A statement for health care professionals from the Nutrition Committee, American Heart Association. Circulation 1999; 99:178–182 [DOI] [PubMed] [Google Scholar]
- 7. Stein JH, McBride PE: Hyperhomocysteinemia and atherosclerotic vascular disease: Pathophysiology, screening, and treatment. Arch Intern Med 1998; 158:1301–1306 [DOI] [PubMed] [Google Scholar]
- 8. Fiore MC, Bailey WC, Cohen SJ, Dorfman SF, Goldstein MG, Gritz ER, Heyman RB, Holbrook J, Jaen CR, Kottke TE, Lando HA, Mecklenburg R, Mullen PD, Nett LM, Robinson L, Stitzer ML, Tommasello AC, Villejo L, Wewers ME: Smoking Cessation. Clinical Practice Guideline No 18 Rockville, Md.: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; AHCPR Publication No. 960692. April 1996. [Google Scholar]
- 9. Serfontein W, Ubbink J, De Villiers L, Becker P: Depressed plasma pyridoxal‐5′‐phosphate levels in tobacco‐smoking men. Atherosclerosis 1986; 59:341–346 [DOI] [PubMed] [Google Scholar]
- 10. Vermaak WJ, Ubbink JB, Barnard HC, Potgieter GM, van Jaarsveld H, Groenewald AJ: Vitamin B‐6 nutrition status and cigarette smoking. Am J Clin Nutr 1990; 51:1058–1061 [DOI] [PubMed] [Google Scholar]
- 11. Piyathilake CJ, Hine RJ, Dasanayake AP, Richards EW, Freeberg LE, Vaughn WH, Krumdieck CL: Effect of smoking on folate levels in buccal mucosal cells. Int J Cancer 1992; 52:566–569 [DOI] [PubMed] [Google Scholar]
- 12. Hughes JR: Harm‐reduction approaches to smoking: The need for data. Am J Prev Med 1998; 15:78–79 [DOI] [PubMed] [Google Scholar]
- 13. Benowitz NL, Gourlay SG: Cardiovascular toxicity of nicotine: Implications for nicotine replacement therapy. J Am Coll Cardiol 1997; 29:1422–1431 [DOI] [PubMed] [Google Scholar]
- 14. Etter JF, Perneger TV, Ronchi A: Distributions of smokers by stage: International comparison and association with smoking prevalence. Prev Med 1997; 26:580–585 [DOI] [PubMed] [Google Scholar]
- 15. Hurt RD, Sachs DPL, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM: A comparison of sustained‐release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337:1195–1202 [DOI] [PubMed] [Google Scholar]
- 16. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB: A controlled trial of sustained‐release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340:685–691 [DOI] [PubMed] [Google Scholar]
- 17. Omenn GS, Beresford SAA, Motulsky AG: Preventing coronary heart disease: B vitamins and homocysteine. Circulation 1998; 97:421–424 [DOI] [PubMed] [Google Scholar]
- 18. Lipid Research Clinics Program : The Lipid Research Clinics Coronary Primary Prevention Trial Results: Reduction in incidence of coronary heart disease. J Am Med Assoc 1984; 251:35 [DOI] [PubMed] [Google Scholar]